IDEAS home Printed from
   My bibliography  Save this paper

Pharmaceutical Pricing and Reimbursement Policies in Mexico


  • Pierre Moïse
  • Elizabeth Docteur


This paper examines aspects of the policy environment and market characteristics of Mexico's pharmaceutical sector, and assesses the degree to which Mexico has achieved certain policy goals. This paper questions the effectiveness of the maximum price regulation. It notes that retail prices for pharmaceuticals are relatively high, although proximity to the United States may have some influence. Although not wholly successful in containing overall drug expenditures, the federal government can claim some measure of success for the public sector market. A high reliance on out-of-pocket spending brings into question the sustainability of financing pharmaceuticals in Mexico. It also contributes to greater inequality, although a new health insurance scheme, the Seguro Popular, is addressing the latter with some success as it endeavours to provide coverage for the half of Mexico's population without health insurance. Finally, the paper acknowledges the government.s efforts in improving efficiency of expenditures and quality of care through new bioequivalency requirements for generics. However, an unintended side-effect of the loss of low cost, non-bioequivalent drugs may be higher average prices for pharmaceuticals. Le présent document examine certains aspects touchant l'environnement politique et les caractéristiques du marché du secteur pharmaceutique du Mexique, et évalue la mesure dans laquelle le Mexique a atteint certains objectifs politiques. Il met en doute l'efficacité de la réglementation sur les prix maximums et fait observer que les prix de détail des produits pharmaceutiques sont relativement élevés, mais que cette situation est peut-être due en partie à la proximité des États-Unis. Bien que le gouvernement fédéral n'ait pas totalement réussi à maîtriser les dépenses globales de médicaments, il peut revendiquer d'un certain succès en ce qui concerne le marché du secteur public. Un large recours aux versements directs amène à s'interroger sur la viabilité du financement des produits pharmaceutiques au Mexique. Un tel recours contribue également à un accroissement des inégalités, bien qu'un nouveau dispositif d'assurance maladie, le Seguro Popular, remédie dans une certaine mesure à ce problème en s'efforçant d'offrir une couverture maladie à la moitié de la population du Mexique qui n'est pas assurée. Enfin, le document fait état des efforts déployés par le gouvernement pour rationaliser les dépenses et améliorer la qualité des soins moyennant l'adoption de nouvelles dispositions en matière de bioéquivalence des médicaments génériques. Cela étant, la disparition des médicaments peu coûteux non bioéquivalents risque d'avoir pour effet involontaire une augmentation des prix moyens des produits pharmaceutiques.

Suggested Citation

  • Pierre Moïse & Elizabeth Docteur, 2007. "Pharmaceutical Pricing and Reimbursement Policies in Mexico," OECD Health Working Papers 25, OECD Publishing.
  • Handle: RePEc:oec:elsaad:25-en

    Download full text from publisher

    File URL:
    Download Restriction: no


    Citations are extracted by the CitEc Project, subscribe to its RSS feed for this item.

    Cited by:

    1. repec:spr:eujhec:v:18:y:2017:i:6:d:10.1007_s10198-016-0857-3 is not listed on IDEAS
    2. Kanavos, Panos, 2014. "Measuring performance in off-patent drug markets: A methodological framework and empirical evidence from twelve EU Member States," Health Policy, Elsevier, vol. 118(2), pages 229-241.
    3. Jürgen Maurer, 2008. "Assessing horizontal equity in medication treatment among elderly Mexicans: which socioeconomic determinants matter most?," Health Economics, John Wiley & Sons, Ltd., vol. 17(10), pages 1153-1169.

    More about this item


    fixation des prix; marché; market; Mexico; Mexique; pharmaceutical policy; politique du médicament; pricing; reimbursement; remboursement;

    JEL classification:

    • I11 - Health, Education, and Welfare - - Health - - - Analysis of Health Care Markets
    • I18 - Health, Education, and Welfare - - Health - - - Government Policy; Regulation; Public Health

    NEP fields

    This paper has been announced in the following NEP Reports:


    Access and download statistics


    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:oec:elsaad:25-en. See general information about how to correct material in RePEc.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (). General contact details of provider: .

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service hosted by the Research Division of the Federal Reserve Bank of St. Louis . RePEc uses bibliographic data supplied by the respective publishers.